GitHub hosts HunyuanVideo, Tencent's open-source framework for large-scale video generation models, enabling AI-driven video creation.
Main

About Main
Main is a generative AI platform focused on longevity and sustainability, offering tools for drug discovery and sustainable chemistry. The platform integrates foundation models fine-tuned for biomedical applications, enabling researchers to generate novel molecular designs and optimize compounds for therapeutic and environmental targets. It automates repetitive tasks in the discovery pipeline, from target identification to lead optimization, reducing time and cost while improving accuracy. Main serves biotech companies, pharmaceutical researchers, and sustainability-focused teams aiming to develop novel therapeutics or eco-friendly materials. The platform is designed to bridge the gap between computational predictions and experimental validation, providing actionable insights for decision-making. Users can explore chemical space efficiently, prioritize candidates based on multi-objective criteria, and collaborate across teams to accelerate innovation in health and sustainability domains.
Insilico Medicine
Hong Kong, Hong Kong · Founded 2014
- Founded
- 2014
- Headquarters
- Hong Kong, Hong Kong
Key features
- Fine-tuned generative AI models for drug discovery
- Automated workflows for molecular design and optimization
- Multi-objective candidate prioritization
- Integration with experimental validation pipelines
- Sustainable chemistry tools for eco-friendly materials
- Collaborative workspace for cross-functional teams
- Real-time insights and decision support
- Scalable cloud-based infrastructure
Use cases
- Accelerating novel drug discovery for longevity-focused therapies
- Designing sustainable chemicals and materials with reduced environmental impact
- Optimizing lead compounds for efficacy and safety in preclinical research
Pros
- Integrates foundation models fine-tuned for biomedical applications to accelerate drug discovery
- Automates repetitive tasks in the discovery pipeline, reducing time and cost
- Bridges computational predictions with experimental validation for actionable insights
- Supports both therapeutic and sustainability-focused applications
- Enables efficient exploration of chemical space and multi-objective candidate prioritization
Cons
- Primarily focused on drug discovery and sustainability, limiting applicability to other domains
- Requires domain expertise in biotech or pharmaceutical research for optimal use
- Integration with existing workflows may require technical adaptation
Frequently asked questions about Main
What does Main do?
Main is a generative AI platform designed for drug discovery, scientific research, and sustainability applications. It uses AI models to automate and optimize molecular design, target identification, and lead optimization.
Who is Main suitable for?
Main is suitable for biotech companies, pharmaceutical researchers, and sustainability-focused teams aiming to develop novel therapeutics or eco-friendly materials.
How does Main integrate with existing workflows?
Main integrates through its Pharma.ai suite, which includes tools like PandaOmics, Chemistry42, and Generative Biologics, designed to streamline and automate various stages of the drug discovery pipeline.
What kind of support does Main offer for collaboration?
Main provides collaborative features across teams, enabling shared access to insights, candidate prioritization, and decision-making tools to accelerate innovation in health and sustainability domains.
Does Main require technical expertise to use?
Yes, Main is designed for users with domain expertise in biotech or pharmaceutical research, as it involves complex AI-driven workflows and molecular design processes.
How can I get started with Main?
Interested users can contact Insilico Medicine through their website to request access or learn more about the platform and its capabilities.
Main Website Engagement
Last Update: 9 days ago
Monthly Traffic
Traffic Sources
Traffic Share By Country
- United States34.9%
- United Kingdom9.9%
- India9%
- Germany8.2%
- Belgium6.3%